CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
IV administration of fluorine-18 fluorocholine followed by PET/CT imagingdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00928174
NCT00928174Phase 2Completed
CompareCT.gov

Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer

Queen's Medical Center·interventional·Posted Jun 25, 2009·Updated Nov 11, 2015

In Brief

A Phase 2 clinical trial evaluating IV administration of fluorine-18 fluorocholine followed by PET/CT imaging for Prostate Cancer. Completed, enrolled 27 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether positron emission tomography / computed tomography (PET/CT) using fluorine-18 fluorocholine as an imaging agent can characterize regional responses to anti-androgen therapies in a manner that in the future aid in the customized planning of treatments for patients with androgen-insensitive prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 25, 2009
Enrollment StartJun 1, 2009
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 17.0 years ago

Interventions

IV administration of fluorine-18 fluorocholine followed by PET/CT imagingdrug

Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.